Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: A highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation

Transplantation

Volumn 77, Issue 8, 2004, Pages 1203-1208

  Di Paolo, Daniele ^a   Tisone, Giuseppe ^a   Piccolo, Paola ^a   Lenci, Ilaria ^a   Zazza, Settimio ^a   Angelico, Mario ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; STEROID; VIRUS DNA;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; ENZYME IMMUNOASSAY; FOLLOW UP; GRAFT REJECTION; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RECURRENT INFECTION; TREATMENT OUTCOME; VIRUS HEPATITIS;

EID: 2342572873     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000118904.63669.EB     Document Type: Article

References (28)

1. Todo S, Demetris A, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus related liver disease. Hepatology 1991; 13: 619.
2. O'Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992; 14: 104.
3. Davies SE, Portman BC, O'Grady IG, et al. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991; 13: 150.
4. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842.
5. Terrault N, Wright TL. Hepatitis B virus infection and liver transplantation. Gut 1997; 40: 568.
6. Lerut JP, Donataccio M, Ciccarelli O, et al. Liver transplantation and HBsAg-positive post-necrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol 1999; 30: 706.
7. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000, summary of a workshop. Gastroenterology 2001; 120: 1828.
8. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189.
9. Celis E, Abraham KG, Miller RW. Modulation of the immunological response to hepatitis B virus by antibodies. Hepatology 1987; 7: 563.
10. Ghany MG, Ayola B, Villamil FG, et al. Hepatitis B virus mutants in liver transplant recipients who are reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998; 27: 213.
11. Lauchart W, Muller R, Pichlmayr R. Long-term immunoprophylaxis of hepatitis B virus reinfection in recipients of human liver allografts. Transpl Proc 1987; 19: 4051.
12. Peters MG, Shouval D, Bonham A, et al. Posttransplantation: future therapies. Semin Liver Dis 2000; 20: 19.
13. Muller R, Lauchart W, Farle M, et al. Simultaneous passive-active immunization for preventing hepatitis B virus reinfection in hepatitis B surface antigen-positive liver transplant recipients. In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York, Liss 1988, pp. 810-812.
14. McGory RW, Ishitani MB, Oliveira WM, et al. Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996; 61: 1358.
15. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after transplantation in HBsAg-positive patients. Lancet 1991; 337: 813.
16. Gugenheim J, Crafa F, Fabiani P, et al. Long-term passive immunoprophylaxis of B virus recurrence after liver transplantation in HBs antigen-positive patients. Transp Proc 1993; 25: 1349.
17. Mutimer D, Dusheiko G, Barrett C, et al. Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: Long-term follow-up. Transplantation 2000; 70: 809.
18. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512.
19. Perrillo RP, Wright T, Rakela J, et al. A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 2001; 33: 424.
20. Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491.
21. Sanchez-Fueyo A, Rimola A, Grande L, et al. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496.
22. Angelico M, Di Paolo D, Trinito MO, et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 2002; 35: 176.
23. Terrault NA, Zhou S, McCory RW, et al. Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin. Hepatology 1998; 28: 555.
24. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520.
25. Agnus PW, McCaughan GW, Gan EJ, et al. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429.
26. al-Hemsi B, McGory RW, Shepard B, et al. Liver transplantation for hepatitis B cirrhosis: clinical sequela of passive immunization. Clin Transplant 1996; 10: 668.
27. CDC. Recommendation of the Immunization Practices Advisory Committee (ACIP) inactivated hepatitis B virus vaccine. MMRW 1982; 31: 317, 327.
28. Dodson SF, de Vera ME, Bonham CA, et al. Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation. Liver Transpl 2000; 6: 434.